idiopathic pulmonary fibrosis Archives
Mar. 27, 2019—Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.
Feb. 1, 2018—Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.
Aug. 18, 2016—Vanderbilt University Medical Center (VUMC) has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF).
Jan. 15, 2015—The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).
Apr. 13, 2012—Vanderbilt’s idiopathic pulmonary fibrosis research group is embarking on a study to determine the prevalence of sleep apnea in people with other interstitial lung diseases.